Wells Fargo & Company Boosts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $262.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective raised by stock analysts at Wells Fargo & Company from $260.00 to $262.00 in a note issued to investors on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s target price suggests a potential upside of 90.96% from the company’s previous close.

A number of other analysts also recently weighed in on ASND. Morgan Stanley restated an “equal weight” rating and issued a $116.00 target price on shares of Ascendis Pharma A/S in a report on Monday, April 22nd. Cantor Fitzgerald restated an “overweight” rating and issued a $173.00 target price on shares of Ascendis Pharma A/S in a report on Friday. Wedbush boosted their target price on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an “outperform” rating in a report on Thursday, February 8th. JPMorgan Chase & Co. upped their price target on shares of Ascendis Pharma A/S from $167.00 to $170.00 and gave the company an “overweight” rating in a report on Friday. Finally, Citigroup upped their price target on shares of Ascendis Pharma A/S from $146.00 to $182.00 and gave the company a “buy” rating in a report on Thursday, February 8th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $173.88.

Ascendis Pharma A/S Stock Down 2.8 %

Ascendis Pharma A/S stock opened at $137.20 on Friday. The company’s 50-day moving average price is $146.67 and its 200-day moving average price is $127.81. Ascendis Pharma A/S has a twelve month low of $83.75 and a twelve month high of $161.00. The company has a market cap of $7.99 billion, a PE ratio of -14.28 and a beta of 0.54.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.15) by $0.49. Ascendis Pharma A/S had a negative net margin of 152.68% and a negative return on equity of 16,574.15%. The firm had revenue of $148.62 million for the quarter, compared to the consensus estimate of $97.02 million. As a group, sell-side analysts expect that Ascendis Pharma A/S will post -4.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC bought a new position in Ascendis Pharma A/S in the 4th quarter worth about $25,000. Private Ocean LLC bought a new position in Ascendis Pharma A/S in the 1st quarter worth about $36,000. Quadrant Capital Group LLC grew its stake in Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 151 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in Ascendis Pharma A/S by 37.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 91 shares in the last quarter. Finally, Signaturefd LLC grew its stake in Ascendis Pharma A/S by 31.9% in the 3rd quarter. Signaturefd LLC now owns 798 shares of the biotechnology company’s stock worth $75,000 after acquiring an additional 193 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.